1083168-87-9

Basic information

• Product Name: 2-Methoxy-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• Synonyms: 2-Methoxy-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine;6-Methoxy-2-picoline-4-boronic acid, pinacol ester
• CAS NO: 1083168-87-9
• Molecular Formula: C13H20BNO3
• Molecular Weight: 249.1138
• Mol File: 1083168-87-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 346.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• PKA: 3.30±0.10(Predicted)
• CAS DataBase Reference: 2-Methoxy-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methoxy-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(1083168-87-9)
• EPA Substance Registry System: 2-Methoxy-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(1083168-87-9)

Safety Data

• Hazardous Substances Data: 1083168-87-9(Hazardous Substances Data)

Usage

Uses

2-Methoxy-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine is an intermediate used to prepare pyridine compounds as modulators of cystic fibrosis transmembrane conductance regulator (CFTR) useful in treatment of CFTR-mediated diseases.

Upstream product

• 63071-03-4 2-methoxy-6-methyl-pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 1083169-00-9 4-bromo-2-methoxy-6-methylpyridine 

Downstream Products

• 1309443-98-8 (2-methoxy-6-methylpyridin-4-yl)boronic acid 

Relevant articles and documents

5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER

Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be

MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS

The present invention relates to morpholinothiazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positi